Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 1181.15, up by 0.75 points or 0.06% from its previous closing of Rs. 1180.40 on the BSE.
The scrip opened at Rs. 1199.45 and has touched a high and low of Rs. 1203.20 and Rs. 1176.35 respectively. So far 26907 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023.
Last one week high and low of the scrip stood at Rs. 1,203.20 and Rs. 1133.55 respectively. The current market cap of the company is Rs. 118775.86 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.35% and 6.66% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (USRLD: Entresto tablets). Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
The group now has 399 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
